Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function

计划入组 32 人 · 首次发布于 2025 年 8 月 26 日

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function

计划入组 24 人 · 首次发布于 2025 年 8 月 27 日

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

计划入组 500 人 · 首次发布于 2025 年 12 月 18 日

Ginkgolides Injection

Shenqifuzheng injection

XingNaoJing Injection

SAVIOR LIFETEC CORPORATION TAINAN BRANCH INJECTION PLANT

Taiwan

Harbin Gloria Pharmaceuticals Co., Ltd.

华仁药业股份有限公司

Gan & Lee's Novel Diabetes Drugs GZR18, GZR4, and GZR101 Achieve Positive Phase 2 Results

Gan & Lee Receives FDA Clearance for Phase II Trial of GZR18 in Obesity and Type 2 Diabetes

Gan & Lee's GZR18 Receives FDA IND Clearance for Phase 2 Obesity Trial